Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep 1;29(17):3259-3261.
doi: 10.1158/1078-0432.CCR-23-1243.

PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology

Dawei Jiang  1   2 , Xiaoli Lan  1   2 , Weibo Cai  3
Affiliations
Comment

PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology

Dawei Jiang et al. Clin Cancer Res. .

Abstract

In a recent study, the authors developed a nectin-4-targeting bicyclic peptide-based radiotracer, 68Ga-N188, for PET imaging of advanced urothelial cancer. Preclinical investigation and first-in-human study in 14 patients demonstrated excellent specificity and sensitivity of 68Ga-N188 in detecting metastases. These promising results support 68Ga-N188 as a companion diagnostic for future personalized cancer therapy. See related article by Duan et al., p. 3395.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

Weibo Cai declares conflict of interest with the following corporations: Actithera, Inc., Rad Source Technologies, Inc., Portrai, Inc., rTR Technovation Corporation, and Four Health Global Pharmaceuticals Inc.. All other authors declare that they have no conflict of interest.

Figures

Figure 1.
Figure 1.
PET imaging of nectin-4 via 68Ga-N188 could enable accurate stratification of cancer patients for targeted therapy, based on non-invasive visualization and quantification of nectin-4 expression level in the tumor tissue. Only patients with high nectin-4 expression in the lesions should undergo targeted therapy with drugs such as enfortumab vedotin, but not those patients with low nectin-4 expression, which can cause unnecessary toxicity and adverse effects. (Figure created with BioRender.com.)
See this image and copyright information in PMC

Comment on

References

    1. Duan X, Xia L, Zhang Z, Ren Y, Pomper MG, Rowe SP, et al. First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma. Clin Cancer Res 2023. doi 10.1158/1078-0432.CCR-23-0609. - DOI - PubMed
    1. Targeting Nectin-4 in Bladder Cancer. Cancer Discov 2017;7(8):OF3 doi 10.1158/2159-8290.CD-NB2017-095. - DOI - PubMed
    1. M MR, Cabaud O, Josselin E, Finetti P, Castellano R, Farina A, et al. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol 2017;28(4):769–76 doi 10.1093/annonc/mdw678. - DOI - PubMed
    1. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2(9):683–93 doi 10.1038/nrc882. - DOI - PubMed
    1. Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: Concept, Design, and Applications. Chem Rev 2020;120(8):3787–851 doi 10.1021/acs.chemrev.9b00738. - DOI - PMC - PubMed

Publication types

MeSH terms